Royalty Pharma holds royalty rights for products developed by GSK, Biogen, and AbbVie.

The entities involved

• GSK →

  British multinational pharmaceutical and biotechnology company

  • Clement Fourny joins Biodextris as CEO, a company that originated as a GSK development center.Mon 15:26
  • GSK acquired Sierra Oncology.Mon 14:28
• Royalty Pharma →

  biopharmaceutical company based in New York City

  • Visteon filed transaction details with the SEC and traded on the Nasdaq stock exchange on June 6, 2026.Sun 17:49
  • Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.Sun 02:34
• Biogen →

  American multinational biotechnology company

  Nothing else this week.

• AbbVie →

  pharmaceutical company

  • MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
  • AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48

Related events

• Royalty Pharma outperformed the market so far this year, based on data from August 6, 2025.Jun 7
• Collaboration revenue realization from Pfizer and GSK backing royalty financing for Spero Therapeutics.Aug 20
• Novartis' trial results are impacting Royalty Pharma's investment decisions.Sep 5
• Pablo Legorreta was named the founder and CEO of Royalty Pharma, which provides funding in exchange for royalty rights.Jun 7